For the first time in several years, Treventis CEO Christopher Barden attended the Redefining Early Stage Investments (RESI) conference (held virtually this year due to COVID-19). This conference is a prominent event for life sciences and medical technology companies looking to raise funds for the next stage of their company development. Treventis was proud to schedule meetings with nearly a dozen investors and organizations with interest in neurodegenerative drug development.